Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference
September 20 2017 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing
novel antivirals to address unmet medical needs, today announced
that M. Michelle Berrey, M.D., M.P.H., President and Chief
Executive Officer of Chimerix, will present a corporate
overview at the Cantor Fitzgerald Global Healthcare
Conference on Wednesday, September 27,
2017 at 10:55 a.m. ET at the InterContinental
New York Barclay Hotel.
A live audio webcast of the presentation will be available on
the Investor Relations section of Chimerix's website
at ir.chimerix.com, where it will be archived for
approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to
discovering, developing and commercializing medicines that improve
outcomes for immunocompromised
patients. Chimerix's proprietary lipid conjugate
technology has produced brincidofovir (BCV, CMX001); CMX157, which
was licensed to ContraVir Pharmaceuticals; and earlier-stage
compounds. In addition, Chimerix has in early-stage
development a new clinical candidate, CMX521, for the treatment
and/or prevention of norovirus. For further information, please
visit Chimerix's website, www.chimerix.com.
CONTACT:Investor Relations: ir@chimerix.com or
Will O’Connor Stern Investor Relations Will@sternir.com
212-362-1200
Media: Becky Vonsiatsky W2O Group bvonsiatsky@w2ogroup.com
413-478-2003
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024